Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia A

Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia A

298877

Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia A

The U.S. Food and Drug Administration (FDA) has approved ASC Therapeutics’ request to open a clinical trial in the U.S. into the safety and early efficacy of ASC618, its second-generation gene therapy for hemophilia A. A Phase 1/2 trial (NCT04676048), set to start this month, will test the one-time therapy in up to 12 adults with moderate to severe hemophilia A. Contact information can be found here; enrollment sites have not yet been disclosed. “FDA’s…

You must be logged in to read/download the full post.